Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02913365|
Recruitment Status : Unknown
Verified September 2016 by Brian Grondin-Beaudoin, Université de Sherbrooke.
Recruitment status was: Recruiting
First Posted : September 23, 2016
Last Update Posted : September 23, 2016
|Condition or disease|
|Hemoptysis Haemoptysis Lung Disease Pneumonia Tuberculosis Bronchiectasis Respiratory Tract Infections Respiratory Tract Diseases Bronchitis Mycobacterium Infections Bronchial Disease Pulmonary Hemorrhage Signs and Symptoms Signs and Symptoms, Respiratory Pathologic Processes Mycosis Hemorrhage Lung Cancer Pulmonary Embolism Arteriovenous Fistula|
Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center.
Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach.
Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center.
The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded.
Descriptive statistical analyses will conducted on the data available.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis in a North-American Tertiary Center at the Beginning of the 21st Century|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||June 2017|
Patients presenting with hemoptysis
Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
- Etiologies of hemoptysis [ Time Frame: 5 years ]Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.
- Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography. [ Time Frame: 5 years ]Determining the sensitivity in obtaining the etiology of the hemoptysis episode of each diagnostic modality that follows : chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography in the diagnosis of different etiologies of hemoptysis.
- All-cause mortality at 2 years [ Time Frame: 2 years ]All-cause mortality at 2 years after the diagnosis of hemoptysis.
- Smoking status [ Time Frame: Day 1 ]Determining the percentage of patients who : never smoked, is an active smoker, former smoker or unknown status.
- Age [ Time Frame: Day 1 ]Determining the average age of the enrolled patients.
- Gender [ Time Frame: Day 1 ]Determining the percentage of each gender of the enrolled patients.
- International Normalized Ratio [ Time Frame: Day 1 ]Determining the median of the international normalized ratio (INR).
- Partial Thromboplastin Time [ Time Frame: Day 1 ]Determining the median of the partial thromboplastin time (PTT).
- Platelet count [ Time Frame: Day 1 ]Determining the average of the platelet count measured per microliter of blood.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02913365
|Contact: Brian Grondin-Beaudoin, MDfirstname.lastname@example.org|
|Contact: Matthieu Poirier, MDemail@example.com|
|Centre Hospitalier Universitaire de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1G2E8|
|Contact: Brian Grondin-Beaudoin, MD 18193461110 firstname.lastname@example.org|
|Contact: Matthieu Poirier, MD 18193461110 email@example.com|
|Sub-Investigator: Amelie Blanchard, MD|
|Principal Investigator:||Brian Grodin-Beaudoin, MD||Université de Sherbrooke|